These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30968444)

  • 1. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema.
    Aygören-Pürsün E; Soteres DF; Nieto-Martinez SA; Christensen J; Jacobson KW; Moldovan D; Van Leerberghe A; Tang Y; Lu P; Vardi M; Schranz J; Martinez-Saguer I
    Pediatr Allergy Immunol; 2019 Aug; 30(5):553-561. PubMed ID: 30968444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing Hereditary Angioedema Attacks in Children Using Cinryze®: Interim Efficacy and Safety Phase 3 Findings.
    Aygören-Pürsün E; Soteres D; Moldovan D; Christensen J; Van Leerberghe A; Hao J; Schranz J; Jacobson KW; Martinez-Saguer I
    Int Arch Allergy Immunol; 2017; 173(2):114-119. PubMed ID: 28662509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
    Lumry WR; Craig T; Zuraw B; Longhurst H; Baker J; Li HH; Bernstein JA; Anderson J; Riedl MA; Manning ME; Keith PK; Levy DS; Caballero T; Banerji A; Gower RG; Farkas H; Lawo JP; Pragst I; Machnig T; Watson DJ
    J Allergy Clin Immunol Pract; 2018; 6(5):1733-1741.e3. PubMed ID: 29391286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
    Lumry WR; Zuraw B; Cicardi M; Craig T; Anderson J; Banerji A; Bernstein JA; Caballero T; Farkas H; Gower RG; Keith PK; Levy DS; Li HH; Magerl M; Manning M; Riedl MA; Lawo JP; Prusty S; Machnig T; Longhurst H;
    Orphanet J Rare Dis; 2021 Feb; 16(1):86. PubMed ID: 33588897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children.
    Reshef A; Grivcheva-Panovska V; Kessel A; Kivity S; Klimaszewska-Rembiasz M; Moldovan D; Farkas H; Gutova V; Fritz S; Relan A; Giannetti B; Magerl M
    Pediatr Allergy Immunol; 2019 Aug; 30(5):562-568. PubMed ID: 30993784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of C1 esterase inhibitor for acute attacks in children with hereditary angioedema.
    Lumry W; Soteres D; Gower R; Jacobson KW; Li HH; Chen H; Schranz J
    Pediatr Allergy Immunol; 2015 Nov; 26(7):674-80. PubMed ID: 26171584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial.
    Riedl MA; Grivcheva-Panovska V; Moldovan D; Baker J; Yang WH; Giannetti BM; Reshef A; Andrejevic S; Lockey RF; Hakl R; Kivity S; Harper JR; Relan A; Cicardi M
    Lancet; 2017 Sep; 390(10102):1595-1602. PubMed ID: 28754491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial.
    Riedl MA; Hurewitz DS; Levy R; Busse PJ; Fitts D; Kalfus I
    Ann Allergy Asthma Immunol; 2012 Jan; 108(1):49-53. PubMed ID: 22192966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents.
    Baker JW; Reshef A; Moldovan D; Harper JR; Relan A; Riedl MA
    J Allergy Clin Immunol Pract; 2017; 5(4):1091-1097. PubMed ID: 28202404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children.
    Lumry W; Manning ME; Hurewitz DS; Davis-Lorton M; Fitts D; Kalfus IN; Uknis ME
    J Pediatr; 2013 May; 162(5):1017-22.e1-2. PubMed ID: 23312695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks.
    Lumry WR; Miller DP; Newcomer S; Fitts D; Dayno J
    Allergy Asthma Proc; 2014; 35(5):371-6. PubMed ID: 25295804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study.
    Fukuda T; Yamagami K; Kawahata K; Suzuki Y; Sasaki Y; Miyagi T; Jacobs I; Lawo JP; Glassman F; Akama H; Hide M; Ohsawa I
    Allergol Int; 2023 Jul; 72(3):451-457. PubMed ID: 36858856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema.
    Riedl MA; Lumry WR; Li HH; Banerji A; Bernstein JA; Ba M; Bjrkander J; Magerl M; Maurer M; Rockich K; Chen H; Schranz J
    Allergy Asthma Proc; 2016 Nov; 37(6):489-500. PubMed ID: 27931305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Craig T; Magerl M; Levy DS; Reshef A; Lumry WR; Martinez-Saguer I; Jacobs JS; Yang WH; Ritchie B; Aygören-Pürsün E; Keith PK; Busse P; Feuersenger H; Pawaskar D; Jacobs I; Pragst I; Doyle MK
    Lancet; 2022 Mar; 399(10328):945-955. PubMed ID: 35219377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study.
    Lumry WR; Martinez-Saguer I; Yang WH; Bernstein JA; Jacobs J; Moldovan D; Riedl MA; Johnston DT; Li HH; Tang Y; Schranz J; Lu P; Vardi M; Farkas H;
    J Allergy Clin Immunol Pract; 2019; 7(5):1610-1618.e4. PubMed ID: 30682573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedema.
    Bernstein JA; Manning ME; Li H; White MV; Baker J; Lumry WR; Davis-Lorton MA; Jacobson KW; Gower RG; Broom C; Fitts D; Schranz J
    J Allergy Clin Immunol Pract; 2014; 2(1):77-84. PubMed ID: 24565773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase.
    Weller K; Maurer M; Fridman M; Supina D; Schranz J; Magerl M
    Allergy Asthma Proc; 2017 Mar; 38(2):143-151. PubMed ID: 28093999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: Safety findings from the COMPACT trial.
    Li HH; Mycroft S; Christiansen S; Wood DN; Feuersenger H; Pawaskar D; Jacobs I
    Allergy Asthma Proc; 2018 Sep; 39(5):365-370. PubMed ID: 30107868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate.
    Zuraw BL; Cicardi M; Longhurst HJ; Bernstein JA; Li HH; Magerl M; Martinez-Saguer I; Rehman SM; Staubach P; Feuersenger H; Parasrampuria R; Sidhu J; Edelman J; Craig T
    Allergy; 2015 Oct; 70(10):1319-28. PubMed ID: 26016741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
    Fukunaga A; Morita E; Miyagi T; Eto K; Shimizu A; Kagami S; Yamamoto H; Vardi M; Tang Y; Wang Y; Hide M
    Arerugi; 2020; 69(3):192-203. PubMed ID: 32435020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.